Program
Immunoglobulin G
Also written as “HYQVIA”, “HyQvia” and “GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.”.
Its studies are mostly in Primary Immunodeficiency Diseases · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Prostatic Neoplasms · Autoimmune Diseases of the Nervous System · Alzheimer Disease, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 60 open or running | phase 4since Apr 12, 2017 | Sep 11, 2015 | none ahead |
| GC Biopharma | 30 open or running | phase 4since Jan 25, 2012 | Mar 14, 2011 | none ahead |
| CSL | 10 open or running | phase 3since May 16, 2008 | May 16, 2008 | none ahead |
| Genmab | 10 open or running | phase 2since May 14, 2020 | May 14, 2020 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 1since May 30, 2025 | May 30, 2025 | none ahead |
| Proclara Biosciences | 10 open or running | phase 1since Dec 23, 2016 | Dec 23, 2016 | none ahead |
Also a collaborator on its studies: takeda-development-center-americas-inc, baxalta-innovations-gmbh-now-part-of-shire, AbbVie and symyoo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 16, 2008First study: phase 3 study in Primary Immunodeficiency DiseasesNew to CSLCSL · NCT00680446 · 41 enrolled · Australia, New Zealand
- Mar 14, 2011GC Biopharma's first study: phase 3 study in SepsisNew to GC BiopharmaGC Biopharma · NCT01315496 · 214 enrolled · Korea, Republic of
- Jan 25, 2012Phase 4 study in Mucocutaneous Lymph Node SyndromeGC Biopharma · NCT01524939 · 45 enrolled · Korea, Republic of
- Sep 11, 2015Takeda's first study: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNew to TakedaTakeda · NCT02549170 · 138 enrolled · United States, Argentina, Brazil and more
- Nov 2, 2016Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingTakeda · NCT02955355 · 85 enrolled · United States, Argentina, Brazil and more
- Dec 23, 2016Proclara Biosciences's first study: phase 1 study in Alzheimer DiseaseNew to Proclara BiosciencesProclara Biosciences · NCT03008161 · 83 enrolled · United States
- Apr 12, 2017Phase 4 study in Primary Immunodeficiency DiseasesTakeda · NCT03116347 · 42 enrolled · Czechia, Denmark, France and more
- Sep 7, 2017Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT03277313 · 44 enrolled · United States
- Nov 21, 2019Phase 2 study in Autoimmune Diseases of the Nervous SystemGC Biopharma · NCT04175522 · 23 enrolled · Korea, Republic of
- May 14, 2020Genmab's first study: phase 2 study in Prostatic NeoplasmsNew to GenmabGenmab · NCT04424641 · 48 enrolled · United States, Denmark, Israel and more
- Jul 7, 2020Phase 1 study in Healthy VolunteersTakeda · NCT04578535 · 51 enrolled · United States
- Mar 20, 2025Phase 1 study in Healthy VolunteersTakeda · NCT06895967 · 30 enrolled · United States
- May 30, 2025Hoffmann-La Roche's first study: phase 1 study in Healthy ParticipantsNew to Hoffmann-La RocheHoffmann-La Roche · NCT07025577 · 82 enrolled · United States
- Oct 19, 2026Primary completion moved from 2028-02-28 to 2029-05-06Date moved laterphase 2 · +14 months · NCT07048262
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07025577Healthy Participants · United States | 1 | Completed | Hoffmann-La Roche | Aug 8, 2025 | 82 |
| NCT06895967Healthy Volunteers · United States | 1 | Completed | Takeda | Jul 24, 2025 | 30 |
| NCT04578535Healthy Volunteers · United States | 1 | Completed | Takeda | Mar 2, 2022 | 51 |
| NCT04424641Prostatic Neoplasms · United States, Denmark, Israel and more | 2 | Terminated | Genmab | Oct 29, 2021 | 48 |
| NCT04175522Autoimmune Diseases of the Nervous System · Korea, Republic of | 2 | Completed | GC Biopharma | Jun 11, 2020 | 23 |
| NCT03277313Primary Immunodeficiency Diseases · United States | 3 | Completed | Takeda | Jul 20, 2022 | 44 |
| NCT03116347Primary Immunodeficiency Diseases · Czechia, Denmark, France and more | 4 | Completed | Takeda | Jan 15, 2021 | 42 |
| NCT03008161Alzheimer Disease · United States | 1 | Completed | Proclara Biosciences | Feb 6, 2019 | 83 |
| NCT02955355Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more | 3 | Completed | Takeda | Jul 4, 2023 | 85 |
| NCT02549170Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more | 3 | Completed | Takeda | Feb 23, 2022 | 138 |
| NCT01524939Mucocutaneous Lymph Node Syndrome · Korea, Republic of | 4 | Completed | GC Biopharma | Sep 2012 | 45 |
| NCT01315496Sepsis · Korea, Republic of | 3 | Terminated | GC Biopharma | Dec 2013 | 214 |
| NCT00680446Primary Immunodeficiency Diseases · Australia, New Zealand | 3 | Completed | CSL | May 2013 | 41 |
How it is read
Names in the registry
- “HYQVIA”, 10 entries
- “Immunoglobulin G”, 3 entries
- “HyQvia”, 1 entry
- “GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.”, 1 entry
- “NPT088”, 1 entry
Conditions, from the studies’ own filings
- Primary Immunodeficiency Diseases, 3 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 2 studies
- Prostatic Neoplasms, 1 study
- Autoimmune Diseases of the Nervous System, 1 study
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.